Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Clinical and Experimental Gastroenterology
|
April 22, 2015
CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease
Emily Wendt, Satish Keshav
Nature Medicine
|
February 5, 2008
Engineering attenuated virus vaccines by controlling replication fidelity
Marco Vignuzzi, Emily Wendt, Raul Andino
Journal of Immunology (Baltimore, Md. : 1950)
|
March 27, 2016
Glucocorticoids Suppress CCR9-Mediated Chemotaxis, Calcium Flux, and Adhesion to MAdCAM-1 in Human T Cells
Emily Wendt, Gemma E White, Helen Ferry, et al.
Journal of Crohn'S & Colitis
|
November 19, 2016
Beyond Histological Remission: Intramucosal Calprotectin as a Potential Predictor of Outcomes in Ulcerative Colitis
Marianne Guirgis, Emily Wendt, Lai Mun Wang, et al.
Journal of Crohn'S & Colitis
|
May 17, 2018
Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease
William J Sandborn, Bal R Bhandari, Charles Randall, et al.
Journal of Crohn'S & Colitis
|
May 31, 2018
A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn's Disease
Stefan Schreiber, Corey A Siegel, Keith A Friedenberg, et al.
Inflammatory Bowel Diseases
|
December 10, 2024
Mediators of Filgotinib Treatment Effects in Ulcerative Colitis: Exploring Circulating Biomarkers in the Phase 2b/3 SELECTION Study
Hiroshi Nakase, Silvio Danese, Walter Reinisch, et al.
Gastroenterology
|
August 8, 2017
Circulating and Tissue-Resident CD4<sup>+</sup> T Cells With Reactivity to Intestinal Microbiota Are Abundant in Healthy Individuals and Function Is Altered During Inflammation
Ahmed N Hegazy, Nathaniel R West, Michael J T Stubbington, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
July 28, 2010
Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease
Matthew J Walters, Yu Wang, Nu Lai, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Clinical and Experimental Gastroenterology
|
April 22, 2015
CCR9 antagonism: potential in the treatment of Inflammatory Bowel Disease
Emily Wendt, Satish Keshav
Nature Medicine
|
February 5, 2008
Engineering attenuated virus vaccines by controlling replication fidelity
Marco Vignuzzi, Emily Wendt, Raul Andino
Journal of Immunology (Baltimore, Md. : 1950)
|
March 27, 2016
Glucocorticoids Suppress CCR9-Mediated Chemotaxis, Calcium Flux, and Adhesion to MAdCAM-1 in Human T Cells
Emily Wendt, Gemma E White, Helen Ferry, et al.
Journal of Crohn'S & Colitis
|
November 19, 2016
Beyond Histological Remission: Intramucosal Calprotectin as a Potential Predictor of Outcomes in Ulcerative Colitis
Marianne Guirgis, Emily Wendt, Lai Mun Wang, et al.
Journal of Crohn'S & Colitis
|
May 17, 2018
Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease
William J Sandborn, Bal R Bhandari, Charles Randall, et al.
Journal of Crohn'S & Colitis
|
May 31, 2018
A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn's Disease
Stefan Schreiber, Corey A Siegel, Keith A Friedenberg, et al.
Inflammatory Bowel Diseases
|
December 10, 2024
Mediators of Filgotinib Treatment Effects in Ulcerative Colitis: Exploring Circulating Biomarkers in the Phase 2b/3 SELECTION Study
Hiroshi Nakase, Silvio Danese, Walter Reinisch, et al.
Gastroenterology
|
August 8, 2017
Circulating and Tissue-Resident CD4<sup>+</sup> T Cells With Reactivity to Intestinal Microbiota Are Abundant in Healthy Individuals and Function Is Altered During Inflammation
Ahmed N Hegazy, Nathaniel R West, Michael J T Stubbington, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
July 28, 2010
Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease
Matthew J Walters, Yu Wang, Nu Lai, et al.
Page
of 1